Fresenius medical care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025

Strong organic revenue growth1 of 10% driven by all operating segments positive u.s. same market treatment growth of 0.1 % in line with expectations accelerated operating income2 growth of 28% at constant currency, leading to a step-change in margin expansion to 11.7% reported operating income grew by 3%, reported net income3 by 29% net leverage ratio further improved to 2.6x, in parallel to share buyback and value-based care investments fy 2025 outlook confirmed bad homburg, germany, nov. 4, 2025 /prnewswire/ -- "in q3 of 2025, we continued the momentum and further accelerated revenue growth. conversion into operating income2 growth increased as planned for the third consecutive quarter, underlining our continued operational and financial progress.
FMS Ratings Summary
FMS Quant Ranking